drugset / Trial / NCT03982004
Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
Phase 1
Terminated
1 enrolled
Washington University School of Medicine
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to look at the safety and side effects of combining the drug pembrolizumab with imiquimod, GM-CSF, and cryotherapy to treat breast cancer that includes skin lesions.
Timeline
- Start
- 2020-09-14
- Primary completion
- 2021-03-03
- Completion
- 2021-03-03
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GM-CSF | Protein / enzyme biologic | 250 ug | Other |
| Subject | Imiquimod | Other / unclassified | — | Topical |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |